CD93 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, a study published in 2020 comparing a total of 878 BM or blood samples from 274 patients with AML, 97 patients with CML, and 288 controls also revealed an aberrant profile of CD25+CD26+/CD56+/CD93+/IL1RAP+ antigens among CD34+CD38− CML cells [11].